This is further supported by the recent KAMILLA trial, which demonstrates that T-DM1 is effective among patients with ERBB2-positive breast cancer BRM.31 Hence, it is not surprising that in our cohort patients with ERBB2-positive breast cancer BRM had the lowest cumulative risk of death and longest OS after treatment with brain radiotherapy. Here, ERBB2 is linked to breast carcinoma.